Novel Regimens in COVID-19 Treatment
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorTanta University
About this trial
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with COVID-19 infection
Disqualifiers
Allergy or contraindication to the drugs.
Trial design
Design model
Parallel
Treatments tested in this trial
Nitazoxanide
DrugNitazoxanide
Treatment groups
160 Participants
are divided into 2 treatment groupsGroup A: NitazoxanideExperimental treatment 1 intervention
Group B: Control groupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Number of patients with virological cure
the number of patients with virological cure
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov